The Food and Drug Administration on Tuesday released a warning letter that it sent to medical device company Dexcom on March 4 citing quality issues at the facilities responsible for testing its ...

FOX21’s Carolynn Felling, a Type One Diabetic herself, said since she last covered the shortage, she has been able to get her ...

Deep-pocketed investors have adopted a bearish approach towards DexCom (NASDAQ:DXCM), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga ...

A warning letter posted Tuesday by the Food and Drug Administration revealed quality control issues with Dexcom’s continuous glucose monitors. The FDA raised concerns with a design change to a ...

Dexcom has won a clearance from the FDA for its longest-lasting continuous glucose monitor, a 15-day version of its flagship G7 sensor. The new system, which boosts wear time up from the previous ...

The Dexcom 15-day G7 continuous glucose monitor (CGM) is accurate and safe for use up to 15.5 days in adults with diabetes. Currently under review by the US Food and Drug Administration ...

In its fourth quarter 2024 investor letter, Sands Capital Select Growth Fund emphasized stocks such as DexCom, Inc. (NASDAQ:DXCM). DexCom, Inc. (NASDAQ:DXCM) is a medical device company that ...

DexCom, Inc. (NASDAQ:DXCM – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the eighteen ratings firms that are covering the firm, MarketBeat Ratings reports.